Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
741 TWT-101: a first-in-clinic study of CFI-402411, a hematopoietic progenitor Kinase-1 (HPK1) inhibitor, as single agent or combined with pembrolizumab in subjects with advanced solid malignancies
Compose a Response to This Article
Other responses
No responses have been published for this article.
